Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Further Reading from MarketBeat Media 2 Small-Cap Biotechs That Could Reward Patient InvestorsWritten by Chris Markoch. Published 12/12/2025. 
Key Points - Small-cap biotech stocks like Mainz Biomed and NanoViricides offer high risk but the potential for outsized returns as their diagnostic and antiviral pipelines advance.
- Mainz Biomed’s ColoAlert test provides early commercial traction, but limited revenue and ongoing cash needs continue to pressure MYNZ stock.
- NanoViricides’ nanomedicine antiviral platform shows promising preclinical data, yet NNVC remains a speculative bet dependent on new funding and pipeline progress.
Speculation and patience rarely go hand in hand. Nevertheless, if you're looking to invest in the small-cap biotech sector, patience is a requirement. Most of these companies are still in the clinical stage, which means they have no commercially available drugs or therapeutics. That also means negative earnings (not profitable) and little to no revenue. Success often hinges on the outcome of a single clinical-stage candidate. While President Trump's official salary is $400,000 per year... his tax returns reveal he's been collecting up to $250,000 PER MONTH from one hidden source. Until recently, most Americans couldn't touch the type of investment that makes up this investment. But thanks to Executive Order 14330, that just changed. If you love investing in disruptive new companies... Discover how to invest in the fund Trump uses to collect this income >> Even if a product advances through trials, profitability may still be years away. Only after reaching that milestone do companies typically receive the analyst coverage that attracts institutional investment. However, if one of these medical stocks hits, returns can be enormous—3x, 5x, or even 10x. Many will fail, which is why investors often spread a lump sum across multiple biotech positions; if it's a numbers game, diversification can be an effective strategy. With that in mind, let's examine two small-cap biotech stocks that carry significant risks but also have the potential for outsized returns. Mainz Biomed: Early Cancer Detection With High Upside Potential Mainz Biomed AG (NASDAQ: MYNZ) is a German molecular diagnostics company that specializes in epigenetics-based tests for early cancer detection. Unlike some penny stocks in this space, Mainz Biomed already has a commercially available product: ColoAlert—the first DNA-based screening tool for colorectal cancer in Europe. On Dec. 2, Mainz Biomed announced that ColoAlert was added to the portfolio of DoctorBox, one of Germany's digital health pioneers. With more than 60,000 new colorectal cancer cases annually in Germany, the market opportunity is significant. The company is also in the early stages of developing a non-invasive, blood-based screening test for early pancreatic cancer detection. Mainz Biomed reported positive topline results in October, but commercialization remains years away. The risks are substantial. ColoAlert is not yet available in the United States, and despite early sales in Europe and plans to expand into South America, revenue remains minimal. That's why the company included “Going Concern” language in its Sept. 26 SEC filing. Since then, Mainz Biomed has filed a $150 million mixed shelf offering. For now, that appears sufficient to keep MYNZ above $1 and avoid a delisting notice. The company is racing to generate enough revenue to move the needle. If successful, even a small investment could yield a sizable return. NanoViricides: High-Risk Antiviral Play With Breakthrough Potential NanoViricides Inc. (NYSE: NNVC) is another micro-cap biotech pursuing a potentially disruptive antiviral approach—but it carries the financial risks speculative investors must weigh carefully. The company is developing a novel class of antiviral therapies based on its proprietary "nanoviricide" platform. These candidates are designed to mimic human cell surfaces and lure viruses into binding with them, effectively neutralizing the pathogens before they can infect real cells. It's an innovative concept that, if validated in human trials, could represent a new method for infectious disease treatment. NanoViricides' pipeline includes candidates targeting shingles (varicella-zoster virus), HSV-1 and HSV-2, and broad-spectrum influenza. Its shingles program, NV-HSC, is the most advanced and has shown encouraging preclinical antiviral activity. But like many micro-cap biotechs, NanoViricides remains pre-revenue and reliant on fresh capital to keep programs moving. The company reported limited cash on hand in recent filings, and investors should expect the possibility of future dilution. Still, if one of its candidates advances into clinical development, the valuation upside could be substantial. For investors with patience and a high tolerance for risk, NNVC represents a genuine moonshot in the antiviral space.
| 
